Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

Invariant Natural Killer T-cell anergy to endogenous myelin acetyl-glycolipids in multiple sclerosis.

Gately CM, Podbielska M, Counihan T, Hennessy M, Leahy T, Moran AP, Hogan EL, O'Keeffe J.

J Neuroimmunol. 2013 Jun 15;259(1-2):1-7. doi: 10.1016/j.jneuroim.2013.02.020. Epub 2013 Mar 26.

PMID:
23537888
2.

Stimulation of a shorter duration in the state of anergy by an invariant natural killer T cell agonist enhances its efficiency of protection from type 1 diabetes.

Tohn R, Blumenfeld H, Haeryfar SM, Veerapen N, Besra GS, Porcelli SA, Delovitch TL.

Clin Exp Immunol. 2011 Apr;164(1):26-41. doi: 10.1111/j.1365-2249.2011.04323.x. Epub 2011 Mar 1.

3.
4.

Novel myelin penta- and hexa-acetyl-galactosyl-ceramides: structural characterization and immunoreactivity in cerebrospinal fluid.

Podbielska M, Dasgupta S, Levery SB, Tourtellotte WW, Annuk H, Moran AP, Hogan EL.

J Lipid Res. 2010 Jun;51(6):1394-406. doi: 10.1194/jlr.M001396. Epub 2010 Feb 12.

5.

β-mannosylceramide activates type I natural killer t cells to induce tumor immunity without inducing long-term functional anergy.

O'Konek JJ, Kato S, Takao S, Izhak L, Xia Z, Illarionov P, Besra GS, Terabe M, Berzofsky JA.

Clin Cancer Res. 2013 Aug 15;19(16):4404-11. doi: 10.1158/1078-0432.CCR-12-2169. Epub 2013 Jun 26.

6.

Activation or anergy: NKT cells are stunned by alpha-galactosylceramide.

Sullivan BA, Kronenberg M.

J Clin Invest. 2005 Sep;115(9):2328-9.

7.

Tuberous sclerosis 1 promotes invariant NKT cell anergy and inhibits invariant NKT cell-mediated antitumor immunity.

Wu J, Shin J, Xie D, Wang H, Gao J, Zhong XP.

J Immunol. 2014 Mar 15;192(6):2643-50. doi: 10.4049/jimmunol.1302076. Epub 2014 Feb 14.

8.

Avidity of CD1d-ligand-receptor ternary complex contributes to T-helper 1 (Th1) polarization and anticancer efficacy.

Wu TN, Lin KH, Chang YJ, Huang JR, Cheng JY, Yu AL, Wong CH.

Proc Natl Acad Sci U S A. 2011 Oct 18;108(42):17275-80. doi: 10.1073/pnas.1114255108. Epub 2011 Oct 10.

9.

Invariant natural killer T cells: innate-like T cells with potent immunomodulatory activities.

Wu L, Gabriel CL, Parekh VV, Van Kaer L.

Tissue Antigens. 2009 Jun;73(6):535-45. doi: 10.1111/j.1399-0039.2009.01256.x. Epub 2009 Apr 8. Review.

PMID:
19392798
10.

Activation of human invariant natural killer T cells with a thioglycoside analogue of α-galactosylceramide.

Hogan AE, O'Reilly V, Dunne MR, Dere RT, Zeng SG, O'Brien C, Amu S, Fallon PG, Exley MA, O'Farrelly C, Zhu X, Doherty DG.

Clin Immunol. 2011 Aug;140(2):196-207. doi: 10.1016/j.clim.2011.03.016. Epub 2011 Apr 13.

PMID:
21493160
11.

Galactose-modified iNKT cell agonists stabilized by an induced fit of CD1d prevent tumour metastasis.

Aspeslagh S, Li Y, Yu ED, Pauwels N, Trappeniers M, Girardi E, Decruy T, Van Beneden K, Venken K, Drennan M, Leybaert L, Wang J, Franck RW, Van Calenbergh S, Zajonc DM, Elewaut D.

EMBO J. 2011 Jun 1;30(11):2294-305. doi: 10.1038/emboj.2011.145. Epub 2011 May 6.

12.

Dissociated expression of natural killer 1.1 and T-cell receptor by invariant natural killer T cells after interleukin-12 receptor and T-cell receptor signalling.

Emoto M, Shimizu T, Koike H, Yoshizawa I, Hurwitz R, Kaufmann SH, Emoto Y.

Immunology. 2010 Jan;129(1):62-74. doi: 10.1111/j.1365-2567.2009.03148.x.

13.

Invariant NKT cell anergy is induced by a strong TCR-mediated signal plus co-stimulation.

Iyoda T, Ushida M, Kimura Y, Minamino K, Hayuka A, Yokohata S, Ehara H, Inaba K.

Int Immunol. 2010 Nov;22(11):905-13. doi: 10.1093/intimm/dxq444.

14.
15.

Production of both IL-27 and IFN-gamma after the treatment with a ligand for invariant NK T cells is responsible for the suppression of Th2 response and allergic inflammation in a mouse experimental asthma model.

Fujita H, Teng A, Nozawa R, Takamoto-Matsui Y, Katagiri-Matsumura H, Ikezawa Z, Ishii Y.

J Immunol. 2009 Jul 1;183(1):254-60. doi: 10.4049/jimmunol.0800520.

16.

Early activation of invariant natural killer T cells in a rheumatoid arthritis model and application to disease treatment.

Miellot-Gafsou A, Biton J, Bourgeois E, Herbelin A, Boissier MC, Bessis N.

Immunology. 2010 Jun;130(2):296-306. doi: 10.1111/j.1365-2567.2009.03235.x. Epub 2010 Jan 27.

17.

T-cells expressing natural killer (NK) receptors are altered in multiple sclerosis and responses to alpha-galactosylceramide are impaired.

O'Keeffe J, Gately CM, Counihan T, Hennessy M, Leahy T, Moran AP, Hogan EL.

J Neurol Sci. 2008 Dec 15;275(1-2):22-8. doi: 10.1016/j.jns.2008.07.007. Epub 2008 Aug 15.

18.

Long-term human coronavirus-myelin cross-reactive T-cell clones derived from multiple sclerosis patients.

Boucher A, Desforges M, Duquette P, Talbot PJ.

Clin Immunol. 2007 Jun;123(3):258-67. Epub 2007 Apr 19.

PMID:
17448727
19.

Hypothesized role of galactocerebroside and NKT cells in the etiology of multiple sclerosis.

Blewett MM.

Med Hypotheses. 2008;70(4):826-30. Epub 2007 Sep 21.

PMID:
17889444
20.

The T-cell pool is anergized in patients with multiple sclerosis in remission.

Fransson ME, Liljenfeldt LS, Fagius J, Tötterman TH, Loskog AS.

Immunology. 2009 Jan;126(1):92-101. doi: 10.1111/j.1365-2567.2008.02881.x. Epub 2008 Jun 24.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk